Il trattamento dell'acromegalia con octreotide, analogo sintetico della somatostatina a lunga durata d'azione.

Translated title of the contribution: Treatment of acromegaly with octreotide, a synthetic analog of somatostatin with extended action

M. Arosio, N. Bazzoni, G. Faglia

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Octreotide, an analog of somatostatin, is a valid tool for the cure of acromegalic disease. This compound has a prolonged half-life and is more selective than native somatostatin in suppressing growth hormone (GH) secretion. Octreotide, 100 micrograms tid sc, decreases GH levels and improves clinical symptoms in about 85% of acromegalic patients, lowering GH to below 5 ng/ml in 45% and to below 2 ng/ml in 17-21%. Octreotide normalizes somatomedin-C (IGF-I) levels in 36-50% of patients. The increase of dosage up to 1500 micrograms/day does not appear useful in poor responsive patients. No adverse effects on other endocrine functions submitted to hypothalamus-pituitary control have been observed. A slight shrinkage of the pituitary tumor is observed in 30-50% of cases. Octreotide therapy is well tolerated and side effects are usually mild. However the possibility of colelithiasis, liver damage and diabetes mellitus in patients with glucose intolerance must be taken into account. In conclusion octreotide is a useful complement to therapeutic means now used for the treatment of acromegaly.

Original languageItalian
Pages (from-to)29-36
Number of pages8
JournalMinerva Endocrinologica
Volume15
Issue number1
Publication statusPublished - Jan 1990

Fingerprint

Acromegaly
Octreotide
Somatostatin
Growth Hormone
Insulin-Like Growth Factor I
Therapeutics
Glucose Intolerance
Pituitary Neoplasms
Hypothalamus
Half-Life
Diabetes Mellitus
Liver

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Il trattamento dell'acromegalia con octreotide, analogo sintetico della somatostatina a lunga durata d'azione. / Arosio, M.; Bazzoni, N.; Faglia, G.

In: Minerva Endocrinologica, Vol. 15, No. 1, 01.1990, p. 29-36.

Research output: Contribution to journalArticle

@article{27b3d654f7984fb59f4bea5890426fbc,
title = "Il trattamento dell'acromegalia con octreotide, analogo sintetico della somatostatina a lunga durata d'azione.",
abstract = "Octreotide, an analog of somatostatin, is a valid tool for the cure of acromegalic disease. This compound has a prolonged half-life and is more selective than native somatostatin in suppressing growth hormone (GH) secretion. Octreotide, 100 micrograms tid sc, decreases GH levels and improves clinical symptoms in about 85{\%} of acromegalic patients, lowering GH to below 5 ng/ml in 45{\%} and to below 2 ng/ml in 17-21{\%}. Octreotide normalizes somatomedin-C (IGF-I) levels in 36-50{\%} of patients. The increase of dosage up to 1500 micrograms/day does not appear useful in poor responsive patients. No adverse effects on other endocrine functions submitted to hypothalamus-pituitary control have been observed. A slight shrinkage of the pituitary tumor is observed in 30-50{\%} of cases. Octreotide therapy is well tolerated and side effects are usually mild. However the possibility of colelithiasis, liver damage and diabetes mellitus in patients with glucose intolerance must be taken into account. In conclusion octreotide is a useful complement to therapeutic means now used for the treatment of acromegaly.",
author = "M. Arosio and N. Bazzoni and G. Faglia",
year = "1990",
month = "1",
language = "Italian",
volume = "15",
pages = "29--36",
journal = "Minerva Endocrinologica",
issn = "0391-1977",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "1",

}

TY - JOUR

T1 - Il trattamento dell'acromegalia con octreotide, analogo sintetico della somatostatina a lunga durata d'azione.

AU - Arosio, M.

AU - Bazzoni, N.

AU - Faglia, G.

PY - 1990/1

Y1 - 1990/1

N2 - Octreotide, an analog of somatostatin, is a valid tool for the cure of acromegalic disease. This compound has a prolonged half-life and is more selective than native somatostatin in suppressing growth hormone (GH) secretion. Octreotide, 100 micrograms tid sc, decreases GH levels and improves clinical symptoms in about 85% of acromegalic patients, lowering GH to below 5 ng/ml in 45% and to below 2 ng/ml in 17-21%. Octreotide normalizes somatomedin-C (IGF-I) levels in 36-50% of patients. The increase of dosage up to 1500 micrograms/day does not appear useful in poor responsive patients. No adverse effects on other endocrine functions submitted to hypothalamus-pituitary control have been observed. A slight shrinkage of the pituitary tumor is observed in 30-50% of cases. Octreotide therapy is well tolerated and side effects are usually mild. However the possibility of colelithiasis, liver damage and diabetes mellitus in patients with glucose intolerance must be taken into account. In conclusion octreotide is a useful complement to therapeutic means now used for the treatment of acromegaly.

AB - Octreotide, an analog of somatostatin, is a valid tool for the cure of acromegalic disease. This compound has a prolonged half-life and is more selective than native somatostatin in suppressing growth hormone (GH) secretion. Octreotide, 100 micrograms tid sc, decreases GH levels and improves clinical symptoms in about 85% of acromegalic patients, lowering GH to below 5 ng/ml in 45% and to below 2 ng/ml in 17-21%. Octreotide normalizes somatomedin-C (IGF-I) levels in 36-50% of patients. The increase of dosage up to 1500 micrograms/day does not appear useful in poor responsive patients. No adverse effects on other endocrine functions submitted to hypothalamus-pituitary control have been observed. A slight shrinkage of the pituitary tumor is observed in 30-50% of cases. Octreotide therapy is well tolerated and side effects are usually mild. However the possibility of colelithiasis, liver damage and diabetes mellitus in patients with glucose intolerance must be taken into account. In conclusion octreotide is a useful complement to therapeutic means now used for the treatment of acromegaly.

UR - http://www.scopus.com/inward/record.url?scp=0025238086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025238086&partnerID=8YFLogxK

M3 - Articolo

C2 - 2274011

AN - SCOPUS:0025238086

VL - 15

SP - 29

EP - 36

JO - Minerva Endocrinologica

JF - Minerva Endocrinologica

SN - 0391-1977

IS - 1

ER -